Dr. Erik Schliep - Managing Director
Erik started as a Bachelor student in Molecular Biotechnology at the Technical University of Munich and continued to study Biochemistry at the Georg-August-University Goettingen for his Masters. Afterwards, he started to work in the departmenf of Prof. Holger Stark (see below) as a PhD student, which he finished in 2018. During his time as a graduate student, he got in contact with the ProteoPlex system and company. Starting as an Application Specialist for the company, he was appointed managing director in 2019, after Joerg Wamser (the former Managing Director; see below) moved on to a different company.
Joerg Wamser - Co-Founder
Joerg started his professional career in 2002 at the BMW Group. After his MBA studies he joined Fraunhofer Venture, the technology transfer organization of the Fraunhofer Gesellschaft. In 2010 he became founder and managing director of the Max-Planck spinoff company KonTEM, that pioneered in the field of phase plate systems in cryo electron microscopy. In 2014, KonTEM was acquired by FEI Company, a NASDAQ-listed leading electron microscope manufacturer which was then acquired by Thermo Fisher. Subsequently, he built up ProteoPlex from 2016. In 2019, he became Managing Director of the Fraunhofer Technology-Transfer Fund (FTTF). Joerg holds a Master of Business Administration (MBA) from Harvard University and a degree in Industrial Engineering from Munich University of Applied Sciences.
Prof. Dr. Holger Stark - Co-Founder
In 1997, Holger graduated with a Ph.D. in Biochemistry from the Fritz-Haber-Institute in Berlin. After assignments at Imperial College London and at the University of Marburg, he became reasearch group leader at the Max-Planck-Institute of Biophysical Chemistry (MPIBPC) in Goettingen in 2000. Since 2008 he is also Professor for molecular cryo electron microscopy at the University of Goettingen. In 2015, he was appointed as a Director at the MPIBPC. He received numerous awards for his research, amongst others the Ernst-Ruska award.
Dr. Ashwin Chari - Co-Founder
Ashwin studied Biology at ETH Zurich, with specialization in Biochemistry, Molecular Biology and Biophysics. Subsequently, he obtained his Ph.D. in Biochemistry from the University of Wuerzburg. From 2010 to 2016 he was a DFG project group leader in the lab of Holger Stark in Goettingen. Since 2016, he is heading the project group "Structural Biochemistry and Mechanisms" at the MPIBPC.
Dr. David Haselbach - Method development
Starting out as an undergraduate student at the University of Potsdam, David did his Bachleors thesis at the MPI for Molecular Genetics in Berlin. Soon after, he continued as a Masters student with the IMPRES in Göttingen, making an excursion for his M.Sc. thesis to the Technical University of Munich. Back in Göttingen, he started his PhD studies in the department of Prof. Holger Stark and was strongly involved in the research and development of the ProteoPlex system and scientific background. Today, he is an independent research group leader at the IMP in Vienna.
Dr. Jan-Martin Kirves - Method development
Jan-Martin, also a former PhD student in the Stark department, was (and still is) entrusted with the main software development of the ProteoPlex system. After finishing his PhD, he left academia to works for an industrial company today.
Joint press release with NovAliX, 27th March 2018
Press release MPG,
7th Nov 2017:
Press release EMBL,
4th Aug 2016:
8th Aug 2016: